Peanut Allergy: Opportunity Analysis and Forecasts to 2027

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Peanut Allergy: Executive Summary

2.1 Intense Growth Expected for Peanut Allergy Market Following Launch of First-in-Class Targeted Therapies

2.2 The Peanut Allergy Market is Currently Dominated by Small Biotech and Start-Up Companies Using Immunotherapies to Desensitize Patients to Peanut

2.3 Vast Unmet Needs Exist in the Peanut Allergy Market

2.4 Abundant Opportunities Remain for New Entrants to Improve Upon and Transform Therapeutic Options for Peanut Allergy

2.5 Launches of Novel Pipeline Products Will Revolutionize the Peanut Allergy Treatment Landscape and Generate Significant Sales

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Symptoms

4.3 Prognosis and Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Peanut Allergy (2017–2027)

5.5.1 Probable Diagnosed Prevalent Cases of Peanut Allergy

5.5.2 Age-Specific Probable Diagnosed Prevalent Cases of Peanut Allergy

5.5.3 Sex-Specific Diagnosed Prevalent Cases of Peanut Allergy

5.5.4 Probable Diagnosed Prevalent Cases of Peanut Allergy with Comorbid Condition

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Current Treatment Options

6.1 Overview

6.2 Diagnosis

6.3 Treatment

6.3.1 Guidelines

6.3.2 Avoidance and Prevention

6.3.3 Acute Reactions

6.3.4 Peanut Desensitization Using Experimental Oral Immunotherapy

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Therapies Promoting Permanent Tolerance to Peanut

7.3 Biomarkers to Improve Diagnostic Sensitivity and Better Evaluate Patient Responses to Treatment

7.3.1 Improved Diagnostic Sensitivity

7.3.2 Biomarkers to Better Evaluate Patient Responses to Immunotherapy Treatment

7.4 Strategies to Minimize Side Effects in Immunotherapy Protocols

7.5 Strategies to Ensure Long-Term Compliance in Immunotherapy Protocols

7.6 Increased Access to Allergy Specialists

7.7 Enhanced Educational and Allergy Management Resources for a Broad Range of Audiences

8 R&D Strategies

8.1 Overview

8.1.1 Peanut Immunotherapies

8.1.2 Immuno-modulating Biologics Targeting Multiple Allergic Diseases

8.2 Clinical Trials Design

8.2.1 Current Clinical Trial Design

8.2.2 Biomarkers: Limitations and Future Outlook

8.2.3 Trial Design for Real-World Applicability

9 Pipeline Assessment

9.1 Overview

9.2 Innovative Early-Stage Approaches

9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Canada

10.4.4 Australia

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Drug Treated Population for Peanut Allergy

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Individual Drug Assumptions

11.3.8 Pricing of Pipeline Agents

11.4 Primary Research – KOLs Interviewed for This Report

11.4.1 KOLs

11.4.2 Payers

11.4.3 Community Allergists

11.5 Primary Research – Prescriber Survey

11.6 About the Authors

11.6.1 Analyst

11.6.2 Therapy Area Director

11.6.3 Epidemiologist

11.6.4 Epidemiology Reviewers

11.6.5 Global Director of Therapy Analysis and Epidemiology

11.6.6 Global Head and EVP of Healthcare Operations and Strategy

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

Table 1: Peanut Allergy: Key Metrics in the 8MM, 2017–2027

Table 2: Symptoms of Peanut-Induced Allergic Reactions

Table 3: Risk Factors and Comorbidities for Peanut Allergy

Table 4: SPT and sIgE Cutoffs for Peanut Allergy Diagnosis

Table 5: Popular Guidelines Available for Peanut Allergy, 2017

Table 6: Clinical Criteria for Diagnosing Anaphylaxis

Table 7: Pharmacologic Management of Anaphylaxis

Table 8: Comparative Assessment of Peanut Immunotherapy Strategies, 2017

Table 9: Clinical Trial Design for Key Immunotherapy Pipeline Agents in Late-stage Development, 2017

Table 10: Comparison of Therapeutic Classes in Late-stage Development for Peanut Allergy

Table 11: Innovative Early-Stage Approaches for Peanut Allergy, 2017

Table 12: Other Drugs in Development for Peanut Allergy, 2017

Table 13: Clinical Benchmark of Key Pipeline Drugs – Peanut Allergy, 2017

Table 14: Commercial Benchmark of Key Pipeline Drugs – Peanut Allergy, 2017

Table 15: Key Events Impacting Sales for Peanut Allergy, 2017–2027

Table 16: Peanut Allergy Market – Global Drivers and Barriers, 2017–2027

Table 17: Key Projected Launch Dates for Peanut Allergy, 2017–2027

Table 18: Key Projected Patent Expiry Dates for Peanut Allergy, 2017–2027

Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global (8MM) Sales Forecast by Geography for Peanut Allergy in 2017 and 2027

Figure 2: Competitive Assessment of Pipeline Drugs Benchmarked Against the SOC, Experimental Peanut OIT, 2017–2027

Figure 3: Hypersensitivity Reaction to Peanut Allergen and Therapeutic Targets

Figure 4: Sensitization to Peanut Allergen and Therapeutic Targets

Figure 5: 8MM, Age-Standardized Probable Diagnosed Prevalence of Peanut Allergy, All Ages, 2017

Figure 6: 8MM, Sources Used and Not Used to Forecast the Probable Diagnosed Prevalent Cases of Peanut Allergy

Figure 7: 8MM, Sources Used to Forecast the Probable Diagnosed Prevalent Cases of Peanut Allergy with Comorbidity of Asthma and AD

Figure 8: 8MM, Sources Used to Forecast the Probable Diagnosed Prevalent Cases of Peanut Allergy with Concomitant Food Allergy and Other Nut Allergy

Figure 9: 8MM, Probable Diagnosed Prevalent Cases of Peanut Allergy, Men and Women, All Ages, 2017

Figure 10: 8MM, Age-Specific Probable Diagnosed Prevalent Cases of Peanut Allergy, Men and Women, N, 2017

Figure 11: 8MM, Sex-Specific Probable Diagnosed Prevalent Cases of Peanut Allergy, All Ages, N, 2017

Figure 12: 8MM, Probable Diagnosed Prevalent Cases of Peanut Allergy with Comorbid Condition, Men and Women, All Ages, N, 2017

Figure 13: Typical Diagnostic Schemes for Peanut Allergy

Figure 14: Typical Management Scheme for an Individual Diagnosed with Peanut Allergy

Figure 15: Addendum Guidelines for Peanut Allergy Prevention

Figure 16: Global (8MM) Use of Different Branded and Generic Epinephrine Auto-injector Devices, 2017

Figure 17: Rates of Epinephrine Auto-injector Prescription to Peanut Allergy Patients in the 8MM, 2017

Figure 18: Unmet Needs and Opportunities in Peanut Allergy, 2017

Figure 19: Estimated Accessibility to Allergists Throughout the 8MM

Figure 20: Overview of the Development Pipeline in Peanut Allergy, 2017

Figure 21: Key Phase II/III Trials for the Pipeline Agents that GlobalData Expects be Licensed for Peanut Allergy in the 8MM During the Forecast Period, 2017

Figure 22: Competitive Assessment of the Pipeline Drugs Benchmarked Against the SOC, Experimental Peanut OIT, 2017

Figure 23: Global (8MM) Sales Forecast for Peanut Allergy, 2017–2027

Figure 24: Global (8MM) Sales Forecast by Geography for Peanut Allergy in 2017 and 2027

Figure 25: Global (8MM) Sales Forecast by Therapy for Peanut Allergy in 2017 and 2027

Figure 26: Global (8MM) Sales Forecast by Age for Viaskin Peanut and AR-101 in 2027

Figure 27: Sales Forecast by Therapy for Peanut Allergy in the US in 2017 and 2027

Figure 28: Sales Forecast by Therapy for Peanut Allergy in the 5EU in 2017 and 2027

Figure 29: Sales Forecast by Therapy for Peanut Allergy in Canada in 2017 and 2027

Figure 30: Sales Forecast by Therapy for Peanut Allergy in Australia in 2017 and 2027